The psoriasis drug market was valued at USD 20.52 billion in 2024 and is projected to grow from USD 22.63 billion in 2025 to USD 56.96 billion by 2034, exhibiting a strong CAGR of 10.8% during the forecast period. This growth is fueled by the increasing prevalence of psoriasis, the expansion of biologic therapies, rising awareness and diagnosis rates, and continuous innovation in immunomodulatory treatments.
Market Overview
Psoriasis is a chronic, immune-mediated skin disease that affects millions of people globally. Characterized by red, scaly patches, the disease often leads to physical discomfort, emotional distress, and increased risk of comorbidities such as psoriatic arthritis, cardiovascular diseases, and depression. The psoriasis drug market includes topical treatments, systemic medications, and biologics designed to control inflammation and prevent flare-ups.
With growing recognition of psoriasis as a serious autoimmune disorder rather than a mere cosmetic issue, investment in research and drug development has surged in recent years. Pharmaceutical advancements are leading to the introduction of highly targeted therapies with fewer side effects, greater efficacy, and improved patient outcomes.
Key Market Growth Drivers
One of the primary drivers of the psoriasis drug market is the increasing prevalence of psoriasis worldwide. According to the World Health Organization (WHO), psoriasis affects about 2–3% of the global population, with a higher concentration in North America and Europe. A growing number of individuals are being diagnosed each year due to improved healthcare access and diagnostic capabilities.
The rising demand for biologic drugs is also propelling market expansion. Biologics such as TNF-alpha inhibitors, IL-17 inhibitors, and IL-23 inhibitors have shown significant promise in treating moderate to severe cases of psoriasis by targeting specific pathways in the immune system. These drugs have transformed the therapeutic landscape by offering long-term disease control and better quality of life.
Increased awareness campaigns, patient education programs, and government initiatives are driving early diagnosis and treatment uptake. Additionally, rising healthcare expenditure and enhanced insurance coverage for chronic disease management are making advanced therapies more accessible.
Technological innovations in drug delivery—such as long-acting injectables, oral small molecules, and topical formulations with enhanced absorption—are further enhancing treatment adherence and effectiveness.
Key Companies
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Celgene Corporation (a subsidiary of Bristol-Myers Squibb)
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- LEO Pharma A/S
- Merck & Co., Inc.
- Novartis AG
- copyright Inc.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- UCB S.A.
Market Challenges
Despite strong growth projections, the psoriasis drug market faces notable challenges. High treatment costs, especially for biologic therapies, remain a significant barrier, particularly in low- and middle-income countries. Biologics often require long-term or lifelong use, which adds to the financial burden on patients and healthcare systems.
Another major concern is adverse side effects and immune system suppression. Some biologics can increase the risk of infections and other complications, raising questions about long-term safety. As a result, patient reluctance and regulatory hurdles can limit the rapid adoption of novel treatments.
Market saturation in developed regions is also becoming an issue, as many patients are already receiving advanced therapy. This may limit future growth opportunities unless innovation continues to drive the development of new classes of drugs with unique mechanisms of action.
Patent expirations of several blockbuster drugs and the growing presence of biosimilars may further intensify market competition and exert downward pricing pressure.
Market Segmentation
Psoriasis Drug Market, Class Outlook (Revenue, USD Billion, 2020-2034)
- Tumor Necrosis Factor Inhibitors
- Interleukin Inhibitors
- Vitamin D Analogues
- Corticosteriods
- Others
Psoriasis Drug Market, Treatment Outlook (Revenue, USD Billion, 2020-2034)
- Topicals
- Systemic
- Biologics
Psoriasis Drug Market, Route of Administration Outlook (Revenue, USD Billion, 2020-2034)
- Oral
- Parenteral
- Topical
Psoriasis Drug Market, Type Outlook (Revenue, USD Billion, 2020-2034)
- Psoriatic Arthritis
- Plaque Psoriasis
- Others
Psoriasis Drug Market, Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Psoriasis Drug Market, Regional Outlook (Revenue, USD Billion, 2020-2034)
- North America
- Class Outlook
- Tumor Necrosis Factor Inhibitors
- Interleukin Inhibitors
- Vitamin D Analogues
- Corticosteriods
- Others
- Treatment Outlook
- Topicals
- Systemic
- Biologics
- Route of Administration Outlook
- Oral
- Parenteral
- Topical
- Type Outlook
- Psoriatic Arthritis
- Plaque Psoriasis
- Others
- Distribution Channel Outlook
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Class Outlook
- Europe
- Class Outlook
- Tumor Necrosis Factor Inhibitors
- Interleukin Inhibitors
- Vitamin D Analogues
- Corticosteriods
- Others
- Treatment Outlook
- Topicals
- Systemic
- Biologics
- Route of Administration Outlook
- Oral
- Parenteral
- Topical
- Type Outlook
- Psoriatic Arthritis
- Plaque Psoriasis
- Others
- Distribution Channel Outlook
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Class Outlook
Explore More:
https://www.polarismarketresearch.com/industry-analysis/global-psoriasis-drug-market
Conclusion
The psoriasis drug market is on a solid growth trajectory, underpinned by rising disease prevalence, expanding access to advanced therapies, and continuous pharmaceutical innovation. While challenges such as cost, safety, and regulatory complexity persist, the future of psoriasis treatment lies in personalized medicine, biologic breakthroughs, and holistic disease management. As healthcare systems worldwide increasingly prioritize dermatological care, the market offers vast potential for investors, providers, and pharmaceutical developers alike.
More Trending Latest Reports By Polaris Market Research:
Dialysis Catheters Market
Percutaneous Coronary Intervention (PCI) Devices Market
Peptide Based Cancer Therapeutics Market
legal Marijuana Market
Coronary Stent Market
Anti-Aging Market
Active Pharmaceutical Ingredient Market
Cancer or Tumor Profiling Market
Telepharmacy Market
Refurbished Medical Imaging Equipment Market
Virtual Clinical Trials Market
AI in Drug Discovery Market
Spatial Genomics & Transcriptomics Market
US Organoid and Spheroid Market
US pneumococcal vaccine market
Contrast Media Injectors Market
Rare Disease Genetic Testing Market
microRNA Market
Cold Plasma Market
Population Health Management Market
Organ Preservation Market
Brain Health Supplements Market
Cell Culture Market
Anesthesia Devices Market
Scar Treatment Market